PDS Biotechnology Co. (NASDAQ:PDSB) Sees Large Drop in Short Interest

PDS Biotechnology Co. (NASDAQ:PDSB) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 5,700,000 shares, a decline of 18.6% from the June 30th total of 7,000,000 shares. Based on an average daily trading volume, of 626,300 shares, the short-interest ratio is presently 9.1 days.

PDS Biotechnology Stock Down 9.4 %

PDSB stock traded down $0.36 during trading on Tuesday, reaching $3.46. The stock had a trading volume of 497,868 shares, compared to its average volume of 751,362. PDS Biotechnology has a 1-year low of $2.53 and a 1-year high of $6.85. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $126.91 million, a P/E ratio of -2.59 and a beta of 1.92. The firm has a fifty day moving average price of $3.25 and a 200 day moving average price of $4.03.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. On average, equities analysts anticipate that PDS Biotechnology will post -1.46 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on PDSB shares. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research note on Wednesday, June 12th. B. Riley lowered their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, June 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PDS Biotechnology in a research report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, PDS Biotechnology has an average rating of “Moderate Buy” and an average target price of $16.67.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors have recently modified their holdings of the stock. Inspirion Wealth Advisors LLC raised its stake in shares of PDS Biotechnology by 1.4% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after purchasing an additional 4,917 shares in the last quarter. Kathleen S. Wright Associates Inc. bought a new stake in shares of PDS Biotechnology during the 1st quarter valued at about $28,000. Tower Research Capital LLC TRC grew its position in shares of PDS Biotechnology by 530.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock valued at $45,000 after buying an additional 7,612 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of PDS Biotechnology during the 4th quarter valued at about $52,000. Finally, Tempus Wealth Planning LLC bought a new stake in shares of PDS Biotechnology during the 2nd quarter valued at about $55,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.